
Opinion|Videos|December 8, 2023
EMERALD Subgroup Analysis in Patients With Visceral and Bone Metastases: Clinical Implication
Author(s)Joyce O'Shaughnessy, MD
A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































